MB 101 - Mustang Bio

Drug Profile

MB 101 - Mustang Bio

Alternative Names: Anti-CD213a2 chimeric antigen receptor T cell therapy; IL13Rα2-specific CAR-T cells - Mustang Bio; MB-101 - Mustang Bio

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 05 May 2016 Positive initial efficacy and adverse events data from a phase I trial in Glioblastoma released by Mustang Bio
  • 14 Mar 2016 Phase-I clinical trials in Glioblastoma in USA (Intracranial) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top